secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0001558370-22-018776
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix opens enrollment in Phase 2a trial of SGX302 for mild-to-moderate psoriasis
--------------------------------------------------------------------------------

- Phase 2a study (HPN-PSR-01) initiating enrollment of up to 42 patients with mild-to-moderate psoriasis.
- Part A open-label (5-10 patients) followed by Part B double-blind 1:1 active vs. placebo for 18 weeks treatment plus 4-week follow-up.
- SGX302 (synthetic hypericin) activated by visible light; efficacy endpoints include lesion clearance and quality of life.
- Psoriasis affects ~7.5M people in U.S. and 60-125M worldwide; Soligenix estimates >$1B global market for SGX302.
- SGX302 also under NDA review for cutaneous T-cell lymphoma (Phase 3 FLASH study).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000155837022018776/0001558370-22-018776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000155837022018776/tmb-20221219x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-018776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer